Anders Hammerich Riis

Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia : A National Population-Based Cohort Study. / Østgård, Lene Sofie Granfeldt; Lund, Jennifer L; Nørgaard, Jan Maxwell et al.

In: Biology of Blood and Marrow Transplantation, Vol. 24, No. 2, 24, 02.2018, p. 314-323.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Østgård, LSG, Lund, JL, Nørgaard, JM, Nørgaard, M, Medeiros, BC, Nielsen, B, Nielsen, OJ, Overgaard, UM, Kallenbach, M, Marcher, CW, Riis, AH & Sengeløv, H 2018, 'Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study', Biology of Blood and Marrow Transplantation, vol. 24, no. 2, 24, pp. 314-323. https://doi.org/10.1016/j.bbmt.2017.10.019

APA

Østgård, L. S. G., Lund, J. L., Nørgaard, J. M., Nørgaard, M., Medeiros, B. C., Nielsen, B., Nielsen, O. J., Overgaard, U. M., Kallenbach, M., Marcher, C. W., Riis, A. H., & Sengeløv, H. (2018). Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study. Biology of Blood and Marrow Transplantation, 24(2), 314-323. [24]. https://doi.org/10.1016/j.bbmt.2017.10.019

CBE

Østgård LSG, Lund JL, Nørgaard JM, Nørgaard M, Medeiros BC, Nielsen B, Nielsen OJ, Overgaard UM, Kallenbach M, Marcher CW, et al. 2018. Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study. Biology of Blood and Marrow Transplantation. 24(2):314-323. https://doi.org/10.1016/j.bbmt.2017.10.019

MLA

Vancouver

Østgård LSG, Lund JL, Nørgaard JM, Nørgaard M, Medeiros BC, Nielsen B et al. Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study. Biology of Blood and Marrow Transplantation. 2018 Feb;24(2):314-323. 24. Epub 2017 Oct 16. doi: 10.1016/j.bbmt.2017.10.019

Author

Østgård, Lene Sofie Granfeldt ; Lund, Jennifer L ; Nørgaard, Jan Maxwell et al. / Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia : A National Population-Based Cohort Study. In: Biology of Blood and Marrow Transplantation. 2018 ; Vol. 24, No. 2. pp. 314-323.

Bibtex

@article{f8bb637bb8114996913cd5c1f30c41b3,
title = "Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study",
abstract = "To examine the outcomes of allogeneic stem cell transplantation (HSCT) in first complete remission (CR1) compared with chemotherapy alone in a population-based setting, we identified a cohort of patients with acute myeloid leukemia (AML) aged 15 to 70 years diagnosed between 2000 and 2014 in Denmark. Using the Danish National Acute Leukemia Registry, we compared relapse risk, relapse-free survival (RFS), and overall survival (OS) between patients with unfavorable cytogenetic features receiving postremission therapy with conventional chemotherapy only versus those undergoing HSCT in CR1. To minimize immortal time bias, we performed Cox proportional hazards regression, included date of allogeneic HSCT as a time-dependent covariate, and stratified the results by age (<60 or ≥60 years) and cytogenetic risk group. Overall, 1031 patients achieved a CR1. Of these, 196 patients (19%) underwent HSCT. HSCT was associated with a lower relapse rate (24% versus 49%) despite a similar median time to relapse (287 days versus 265 days). In all subgroups, the risk of relapse was lower and both RFS and OS were superior in recipients of HSCT (OS, adjusted mortality ratios: all patients, .54 [95% confidence interval (CI), .42-.71]; patients age <60 years, .58 [95% CI, .42-.81]; patients age ≥60 years, .42 [95% CI, .26-.69]; patients with intermediate-risk cytogenetics, .63 [95% CI, .43-.87]; patients with adverse-risk cytogenetics, .40 [95% CI, .24-.67]). In conclusion, in this population-based nationwide cohort study, HSCT was associated with improved survival in both younger and older patients and in patients with both intermediate and adverse cytogenetic risk.",
author = "{\O}stg{\aa}rd, {Lene Sofie Granfeldt} and Lund, {Jennifer L} and N{\o}rgaard, {Jan Maxwell} and Mette N{\o}rgaard and Medeiros, {Bruno C} and Bendt Nielsen and Nielsen, {Ove Juul} and Overgaard, {Ulrik Malthe} and Maria Kallenbach and Marcher, {Claus Werenberg} and Riis, {Anders Hammerich} and Henrik Sengel{\o}v",
note = "Copyright {\textcopyright} 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.",
year = "2018",
month = feb,
doi = "10.1016/j.bbmt.2017.10.019",
language = "English",
volume = "24",
pages = "314--323",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia

T2 - A National Population-Based Cohort Study

AU - Østgård, Lene Sofie Granfeldt

AU - Lund, Jennifer L

AU - Nørgaard, Jan Maxwell

AU - Nørgaard, Mette

AU - Medeiros, Bruno C

AU - Nielsen, Bendt

AU - Nielsen, Ove Juul

AU - Overgaard, Ulrik Malthe

AU - Kallenbach, Maria

AU - Marcher, Claus Werenberg

AU - Riis, Anders Hammerich

AU - Sengeløv, Henrik

N1 - Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

PY - 2018/2

Y1 - 2018/2

N2 - To examine the outcomes of allogeneic stem cell transplantation (HSCT) in first complete remission (CR1) compared with chemotherapy alone in a population-based setting, we identified a cohort of patients with acute myeloid leukemia (AML) aged 15 to 70 years diagnosed between 2000 and 2014 in Denmark. Using the Danish National Acute Leukemia Registry, we compared relapse risk, relapse-free survival (RFS), and overall survival (OS) between patients with unfavorable cytogenetic features receiving postremission therapy with conventional chemotherapy only versus those undergoing HSCT in CR1. To minimize immortal time bias, we performed Cox proportional hazards regression, included date of allogeneic HSCT as a time-dependent covariate, and stratified the results by age (<60 or ≥60 years) and cytogenetic risk group. Overall, 1031 patients achieved a CR1. Of these, 196 patients (19%) underwent HSCT. HSCT was associated with a lower relapse rate (24% versus 49%) despite a similar median time to relapse (287 days versus 265 days). In all subgroups, the risk of relapse was lower and both RFS and OS were superior in recipients of HSCT (OS, adjusted mortality ratios: all patients, .54 [95% confidence interval (CI), .42-.71]; patients age <60 years, .58 [95% CI, .42-.81]; patients age ≥60 years, .42 [95% CI, .26-.69]; patients with intermediate-risk cytogenetics, .63 [95% CI, .43-.87]; patients with adverse-risk cytogenetics, .40 [95% CI, .24-.67]). In conclusion, in this population-based nationwide cohort study, HSCT was associated with improved survival in both younger and older patients and in patients with both intermediate and adverse cytogenetic risk.

AB - To examine the outcomes of allogeneic stem cell transplantation (HSCT) in first complete remission (CR1) compared with chemotherapy alone in a population-based setting, we identified a cohort of patients with acute myeloid leukemia (AML) aged 15 to 70 years diagnosed between 2000 and 2014 in Denmark. Using the Danish National Acute Leukemia Registry, we compared relapse risk, relapse-free survival (RFS), and overall survival (OS) between patients with unfavorable cytogenetic features receiving postremission therapy with conventional chemotherapy only versus those undergoing HSCT in CR1. To minimize immortal time bias, we performed Cox proportional hazards regression, included date of allogeneic HSCT as a time-dependent covariate, and stratified the results by age (<60 or ≥60 years) and cytogenetic risk group. Overall, 1031 patients achieved a CR1. Of these, 196 patients (19%) underwent HSCT. HSCT was associated with a lower relapse rate (24% versus 49%) despite a similar median time to relapse (287 days versus 265 days). In all subgroups, the risk of relapse was lower and both RFS and OS were superior in recipients of HSCT (OS, adjusted mortality ratios: all patients, .54 [95% confidence interval (CI), .42-.71]; patients age <60 years, .58 [95% CI, .42-.81]; patients age ≥60 years, .42 [95% CI, .26-.69]; patients with intermediate-risk cytogenetics, .63 [95% CI, .43-.87]; patients with adverse-risk cytogenetics, .40 [95% CI, .24-.67]). In conclusion, in this population-based nationwide cohort study, HSCT was associated with improved survival in both younger and older patients and in patients with both intermediate and adverse cytogenetic risk.

U2 - 10.1016/j.bbmt.2017.10.019

DO - 10.1016/j.bbmt.2017.10.019

M3 - Journal article

C2 - 29051022

VL - 24

SP - 314

EP - 323

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

M1 - 24

ER -